Medostatin

Lovastatin, the active ingredient in Medostatin, is an HMG‑CoA reductase inhibitor presented as a tablet for oral use. It lowers elevated LDL cholesterol in adults with hypercholesterolemia.

GNH USA supplies Medostatin as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lovastatin is used to manage disorders of lipid metabolism and to reduce cardiovascular risk.

Hypercholesterolemia: reduces LDL‑cholesterol levels and improves overall lipid profile. Primary hyperlipidemia: lowers total cholesterol and triglycerides in patients with elevated lipid values. Prevention of cardiovascular disease: decreases the risk of myocardial infarction and stroke in patients with high LDL‑cholesterol.

Lovastatin may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Muscle aches or weakness - Abdominal discomfort or constipation - Headache - Nausea or dyspepsia - Dizziness - Elevated liver enzymes (transient)

Serious or Rare Side Effects: - Rhabdomyolysis with severe muscle breakdown - Acute hepatitis or severe liver injury - Anaphylactic or severe allergic reactions - Pancreatitis - Myopathy with marked CK elevation - Severe cutaneous reactions (e.g., Stevens‑Johnson syndrome)

Before initiating therapy, consider the following safety measures.

Pregnancy: contraindicated (Category X); avoid use during pregnancy. Liver disease: assess hepatic function; avoid in active liver disease. Drug interactions: review concomitant medications, especially strong CYP3A4 inhibitors. Renal impairment: monitor renal function; dose adjustment may be required. Monitoring: periodic liver‑function tests and creatine kinase levels are recommended. Store at room temperature: keep in original container, protect from moisture and direct sunlight.

Lovastatin interacts with several drug classes; awareness helps prevent adverse events.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., itraconazole, clarithromycin) - Grapefruit juice - Concomitant use with gemfibrozil (fibrate)

Moderate Interactions (Monitor Closely): - Warfarin: may increase INR; monitor coagulation parameters. - Digoxin: plasma levels may rise; observe for toxicity signs.